1. Home
  2. Live Updates
  3. Translational medicine

Live Breaking News & Updates on Translational medicine

Stay informed with the latest breaking news from Translational medicine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Translational medicine and stay connected to the pulse of your community

Wyss scholars named, UM works on tuberculosis vaccine, lawmakers vote against abortion initiative

UM announces Wyss Scholars for U.S. Conservation

Miami-university , Ohio , United-states , Wyoming , Texas , University-of-montana , Montana , Chile , Idaho-state-university , Idaho , Montanan , Chilean

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

James-hamilton , Nasdaq , Linkedin , Exchange-commission , Arrowhead-pharmaceuticals-inc , Arrowhead-pharmaceuticals , Translational-medicine , Harbor-statement , Private-securities-litigation-reform-act , Annual-report , Quarterly-reports ,

Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB

Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James-hamilton , Nasdaq , Arrowhead-pharmaceuticals-inc , Arrowhead-pharmaceuticals , Translational-medicine ,

Remember "Contagion?" A New Treatment For Nipah Virus Could Be A Game Changer

The movie virus was inspired by the real-life Nipah virus, which causes a deadly infection of the brain.

Philippines , Bangladesh , India , Malaysia , Singapore , Australia , Malaysian , Singaporean , Gwyneth-paltrow , Uniformed-services-university , University-of-texas-medical-branch , Translational-medicine

Infertile Men's Testicular Maldescent May Indicate Severe Genetic Syndrome

Infertile Men's Testicular Maldescent May Indicate Severe Genetic Syndrome
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Tartu , Tartumaa , Estonia , Margus-punab-andrology , University-of-tartu , Infertility-initiative , Andrology-clinic-of-tartu-university-hospital , Maris-laan-institute-of-biomedicine , Tartu-university-hospital , Andrology-clinic , Tartu-university , Maris-laan

Testicular maldescent in infertile men may be a sign of a more severe genetic syndrome

Testicular maldescent in infertile men may be a sign of a more severe genetic syndrome
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Tartu , Tartumaa , Estonia , Anna-grete-juchnewitsch , Margus-punab-andrology , Andero-kalju , Andrology-clinic-of-tartu-university-hospital , Tartu-university-hospital , University-of-tartu , Infertility-initiative , Maris-laan-institute-of-biomedicine , Andrology-clinic

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...

Spain , Beerse , Region-flamande , Belgium , Edmond-chan , Drug-administration , European-union , Committee-for-orphan-medicinal-products , Janssen-cilag-international , European-medicines-agency , European-commission , Johnson

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact:




Investor contact:




...

Spain , United-states , China , Belgium , Beerse , Region-flamande , Chinese , American , Edmond-chan , Jenni-mildon , Ciltacabtagene-autoleucel , European-commission-grants-conditional-approval

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Spain , Edmond-chan , Johnson-company , Johnson , European-commission , Therapeutic-area-lead-for-haematology-at-janssen-cilag , San-miguel , Translational-medicine , Universidad-de-navarra , Area-lead , Janssen-cilag-limited , Multiple-myeloma

Path to a better TB vaccine runs through Montana

A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.

Montana , United-states , Missoula , University-of-montana , Harvard-university , Massachusetts , Chile , Boston , Alemnew-dagnew , Jay-evans , Jim-robbins , Bacille-calmette-gu